PT2981624T - Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro - Google Patents
Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancroInfo
- Publication number
- PT2981624T PT2981624T PT147794036T PT14779403T PT2981624T PT 2981624 T PT2981624 T PT 2981624T PT 147794036 T PT147794036 T PT 147794036T PT 14779403 T PT14779403 T PT 14779403T PT 2981624 T PT2981624 T PT 2981624T
- Authority
- PT
- Portugal
- Prior art keywords
- assessing
- materials
- methods
- homologous recombination
- recombination deficiency
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361809105P | 2013-04-05 | 2013-04-05 | |
| US201361913762P | 2013-12-09 | 2013-12-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2981624T true PT2981624T (pt) | 2020-03-23 |
Family
ID=51659359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT147794036T PT2981624T (pt) | 2013-04-05 | 2014-04-04 | Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20140363521A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2981624B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6625045B2 (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014248007B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2908745C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2981624T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2777228T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2981624T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014165785A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012027224A1 (en) | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| EP3225697A3 (en) | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| WO2012174378A2 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| CN107267598B (zh) | 2011-12-21 | 2022-03-25 | 美瑞德生物工程公司 | 用于评估杂合性丢失的方法与材料 |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA3126823C (en) | 2012-06-07 | 2023-04-04 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| EP2981624B1 (en) * | 2013-04-05 | 2019-12-18 | Myriad Genetics, Inc. | Methods for assessing homologous recombination deficiency and predicting response to cancer treatment |
| EP3080292B1 (en) | 2013-12-09 | 2022-02-02 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| US10545151B2 (en) | 2014-02-21 | 2020-01-28 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| ES2946251T3 (es) | 2014-08-15 | 2023-07-14 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga |
| CA2967447C (en) * | 2014-12-05 | 2025-07-08 | Foundation Medicine, Inc. | MULTIGEN ANALYSIS OF TUMOR SAMPLES |
| EP3230472A4 (en) * | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| WO2016185406A1 (en) | 2015-05-19 | 2016-11-24 | Nadathur Estates Pvt. Ltd. | Method for identification of a deficient brca1 function |
| JP7043412B2 (ja) | 2015-11-03 | 2022-03-29 | エピック サイエンシス， インコーポレイテッド | 疾患の不均一性を特徴づけるための転移性疾患における、循環腫瘍細胞（ｃｔｃ）の単一細胞ゲノムプロファイリング |
| WO2017106365A1 (en) * | 2015-12-14 | 2017-06-22 | Myriad Genetics, Inc. | Methods for measuring mutation load |
| WO2017120324A1 (en) * | 2016-01-06 | 2017-07-13 | Epic Sciences, Inc. | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
| WO2017165270A1 (en) * | 2016-03-21 | 2017-09-28 | Myriad Genetics, Inc. | Homologous recombination deficiency to predict neoadjuvant chemotherapy necessity in bladder cancer |
| WO2017178509A1 (en) | 2016-04-12 | 2017-10-19 | Xentech | Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients |
| WO2017191076A1 (en) | 2016-05-01 | 2017-11-09 | Genome Research Limited | Method of characterising a dna sample |
| JP7224185B2 (ja) * | 2016-05-01 | 2023-02-17 | ゲノム・リサーチ・リミテッド | Ｄｎａサンプルを特徴付ける方法 |
| GB2555765A (en) | 2016-05-01 | 2018-05-16 | Genome Res Ltd | Method of detecting a mutational signature in a sample |
| KR20230042136A (ko) * | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| KR20210035167A (ko) | 2018-06-11 | 2021-03-31 | 파운데이션 메디신 인코포레이티드 | 게놈 변경을 평가하기 위한 조성물 및 방법 |
| JPWO2020137076A1 (ja) * | 2018-12-28 | 2021-11-11 | 国立大学法人 東京大学 | Ｐａｒｐ阻害剤に対する癌の感受性の予測方法および相同組換修復不全を有する癌の検出方法 |
| JP7368483B2 (ja) | 2019-02-12 | 2023-10-24 | テンパス ラブズ，インコーポレイテッド | 相同組換え欠損を推定するための統合された機械学習フレームワーク |
| EP4073805B1 (en) | 2019-12-10 | 2024-07-17 | Tempus AI, Inc. | Systems and methods for predicting homologous recombination deficiency status of a specimen |
| JP2023506084A (ja) * | 2019-12-16 | 2023-02-14 | アジレント・テクノロジーズ・インク | ゲノム瘢痕アッセイ及び関連する方法 |
| EP3945525A1 (en) | 2020-07-27 | 2022-02-02 | Sophia Genetics S.A. | Methods for identifying chromosomal spatial instability such as homologous repair deficiency in low coverage next-generation sequencing data |
| CN111883211B (zh) * | 2020-08-07 | 2021-04-23 | 张哲� | 一种表征hrd同源重组修复缺陷的基因瘢痕及鉴定方法 |
| US11718869B2 (en) * | 2020-08-12 | 2023-08-08 | Zhenyue Biotechnology Jiangsu Co., Ltd. | Method and kit for determining genome instability based on next generation sequencing (NGS) |
| CN112410423B (zh) * | 2020-11-03 | 2021-08-13 | 南京世和基因生物技术股份有限公司 | 同源重组缺失的标志物、检测方法以及检测系统 |
| EP4274908A1 (en) * | 2021-01-10 | 2023-11-15 | Act Genomics (IP) Limited | Homologous recombination deficiency determining method and kit thereof |
| BE1029144B1 (fr) | 2021-02-25 | 2022-09-20 | Oncodna | Méthode de caracterisation d'une tumeur à l'aide d'un séquençage ciblé |
| CN112820351A (zh) * | 2021-03-01 | 2021-05-18 | 江苏医联生物科技有限公司 | 检测肿瘤患者的突变和hrd评分指导用药的方法 |
| EP4360094A4 (en) * | 2021-06-25 | 2025-04-23 | Foundation Medicine, Inc. | SYSTEM AND METHOD FOR CLASSIFYING AN APPROVED REPAIR DEFICIENCY |
| AR127880A1 (es) * | 2021-12-08 | 2024-03-06 | Myriad Genetics Inc | Métodos y materiales para evaluar la deficiencia de recombinación homóloga en subtipos de cáncer de mama |
| KR102523938B1 (ko) * | 2022-02-04 | 2023-04-19 | 가톨릭대학교 산학협력단 | 상동 재조합 결핍증 예측 모델의 모델링 방법 |
| EP4605937A1 (en) | 2022-10-19 | 2025-08-27 | Vib Vzw | Method of determining loss of heterozygosity status of a tumor |
| WO2025078387A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Method of detecting loss of heterozygosity status of a tumor |
| WO2025078404A1 (en) | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1432562A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum co-ordination compounds |
| GB1432563A (en) | 1972-04-10 | 1976-04-22 | Rustenburg Platinum Mines Ltd | Platinum- co-ordination compounds |
| ES444380A1 (es) | 1976-01-16 | 1977-06-16 | Gosalvez Mario | Un procedimiento para preparar derivados metalicos antraci- clinicos. |
| US4950738A (en) | 1984-09-13 | 1990-08-21 | Cytogen Corporation | Amine derivatives of anthracycline antibiotics |
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US5295944A (en) | 1991-05-14 | 1994-03-22 | Dana-Farber Cancer Institute | Method for treating a tumor with ionizing radiation |
| NZ245112A (en) | 1991-11-15 | 1995-07-26 | Smithkline Beecham Corp | Pharmaceutical composition comprising a camptothecin analog and a platinum coordination compound |
| GB9806324D0 (en) | 1998-03-24 | 1998-05-20 | Pharmacia & Upjohn Spa | Antitumour synergetic composition |
| ATE478664T1 (de) | 2000-12-01 | 2010-09-15 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| GB0121285D0 (en) | 2001-09-03 | 2001-10-24 | Cancer Res Ventures Ltd | Anti-cancer combinations |
| US7754684B2 (en) | 2003-06-11 | 2010-07-13 | Access Pharmaceuticals, Inc. | Macromolecular platinum chelates |
| US7485707B2 (en) | 2003-07-02 | 2009-02-03 | Solux Corporation | Thermally stable crystalline epirubicin hydrochloride and method of making the same |
| ATE454893T1 (de) | 2003-07-25 | 2010-01-15 | Cancer Rec Tech Ltd | Tricyclische parp-hemmer |
| WO2005016946A2 (en) | 2003-08-13 | 2005-02-24 | University Of South Florida | Platinum complexes for the treatment of tumors |
| CN101495459A (zh) | 2005-06-30 | 2009-07-29 | 比奥纽默里克药物公司 | 单吡咯配体铂类似物 |
| KR100925337B1 (ko) * | 2009-05-25 | 2009-11-09 | 주식회사 마크로젠 | 염색체 수 이상 검출을 통한 유방암 약물 반응성 예측 |
| DK3327148T3 (da) | 2010-06-18 | 2021-04-12 | Myriad Genetics Inc | Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle |
| WO2012027224A1 (en) * | 2010-08-24 | 2012-03-01 | Dana-Farber Cancer Institute, Inc. | Methods for predicting anti-cancer response |
| EP3415915B1 (en) * | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| EP2981624B1 (en) * | 2013-04-05 | 2019-12-18 | Myriad Genetics, Inc. | Methods for assessing homologous recombination deficiency and predicting response to cancer treatment |
-
2014
- 2014-04-04 EP EP14779403.6A patent/EP2981624B1/en active Active
- 2014-04-04 AU AU2014248007A patent/AU2014248007B2/en active Active
- 2014-04-04 EP EP19216740.1A patent/EP3693475A1/en active Pending
- 2014-04-04 JP JP2016506657A patent/JP6625045B2/ja active Active
- 2014-04-04 PT PT147794036T patent/PT2981624T/pt unknown
- 2014-04-04 ES ES14779403T patent/ES2777228T3/es active Active
- 2014-04-04 CA CA2908745A patent/CA2908745C/en active Active
- 2014-04-04 WO PCT/US2014/033014 patent/WO2014165785A2/en not_active Ceased
- 2014-04-04 US US14/245,576 patent/US20140363521A1/en not_active Abandoned
- 2014-04-04 DK DK14779403.6T patent/DK2981624T3/da active
-
2017
- 2017-07-17 US US15/651,652 patent/US20180030544A1/en not_active Abandoned
-
2019
- 2019-04-26 JP JP2019085187A patent/JP7522539B2/ja active Active
-
2020
- 2020-06-17 AU AU2020204028A patent/AU2020204028B2/en active Active
- 2020-11-25 JP JP2020194936A patent/JP7522643B2/ja active Active
-
2021
- 2021-06-21 US US17/353,279 patent/US20210310079A1/en active Pending
-
2022
- 2022-08-04 AU AU2022211880A patent/AU2022211880B2/en active Active
- 2022-10-21 JP JP2022169085A patent/JP7641938B2/ja active Active
-
2025
- 2025-02-25 JP JP2025027653A patent/JP2025090619A/ja active Pending
- 2025-03-24 US US19/088,496 patent/US20250223655A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3693475A1 (en) | 2020-08-12 |
| ES2777228T3 (es) | 2020-08-04 |
| JP7641938B2 (ja) | 2025-03-07 |
| EP2981624A2 (en) | 2016-02-10 |
| JP7522643B2 (ja) | 2024-07-25 |
| AU2014248007A1 (en) | 2015-10-15 |
| US20180030544A1 (en) | 2018-02-01 |
| EP2981624A4 (en) | 2016-11-30 |
| NZ712663A (en) | 2021-07-30 |
| JP2019165731A (ja) | 2019-10-03 |
| US20250223655A1 (en) | 2025-07-10 |
| AU2020204028B2 (en) | 2022-08-18 |
| CA2908745C (en) | 2023-03-14 |
| DK2981624T3 (da) | 2020-03-02 |
| JP2016523511A (ja) | 2016-08-12 |
| AU2014248007B2 (en) | 2020-03-26 |
| AU2020204028A1 (en) | 2020-07-09 |
| US20210310079A1 (en) | 2021-10-07 |
| EP2981624B1 (en) | 2019-12-18 |
| US20140363521A1 (en) | 2014-12-11 |
| JP2025090619A (ja) | 2025-06-17 |
| JP7522539B2 (ja) | 2024-07-25 |
| WO2014165785A2 (en) | 2014-10-09 |
| AU2022211880B2 (en) | 2025-05-29 |
| AU2022211880A1 (en) | 2022-09-01 |
| JP6625045B2 (ja) | 2019-12-25 |
| JP2021036903A (ja) | 2021-03-11 |
| CA2908745A1 (en) | 2014-10-09 |
| JP2023012488A (ja) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2981624T (pt) | Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro | |
| PT3180447T (pt) | Métodos e materiais para avaliar a deficiência de recombinação homóloga | |
| IL245573A0 (en) | cell | |
| SI2976013T1 (sl) | Postopki za ocenjevanje eritema | |
| ZA201505705B (en) | Phi-4 polypeptides and methods for their use | |
| EP3084626A4 (en) | AUTOMATED EXPERIMENTAL PLATFORM | |
| GB201313423D0 (en) | Compositions and methods | |
| GB201308072D0 (en) | Compositions and methods | |
| GB201201100D0 (en) | Polypeptides and methods | |
| GB201305813D0 (en) | Compositions and methods | |
| IL243361B (en) | Radioactively labeled material | |
| GB201308066D0 (en) | Mattress materials | |
| SG10201708046YA (en) | Nanoprobe-Based Genetic Testing | |
| GB201312332D0 (en) | Cell locations | |
| GB2515832B (en) | Receptacle | |
| GB201317355D0 (en) | Mutation Analysis | |
| GB201310558D0 (en) | Genetic test | |
| IL240033B (en) | A method to assess the aging of a cell | |
| GB2520506B (en) | Partial Scan Cell | |
| HUE035872T2 (hu) | Raktár és raktározási eljárás | |
| GB201314622D0 (en) | Material inspection | |
| GB201315372D0 (en) | Barbecue/cook-station | |
| GB201210303D0 (en) | Polypeptides and methods | |
| GB201320801D0 (en) | Particle Characterization | |
| GB201320573D0 (en) | T Cell |